Abstract
BackgroundWe have previously demonstrated adaptive antibody responses targeting public tumor antigens in cancer patients. ATRC-101, a clinical stage, engineered version of an antibody identified in such a patient, displays robust...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have